Takeaways from the AP’s report on turmoil surrounding the FDA’s new fast-track drug program

WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and outside experts, with some saying the poorly defined effort is taking key decisions away from career scientists and placing them in the hands of political leade...

Redirecting to full article...